Global Transthyretin Amyloid Cardiomyopathy Treatment Market, By Drug (Inostersen, Nonsteroidal Anti-Inflammatory Drugs (NSAID), Partisiran, Tafamidis, Others), Indication (Wild Type ATTR Amyloidosis, Hereditary ATTR Amyloidosis), End- Users (Hospitals, Homecare, Specialty Clinics, Ambulatory Surgical Centers, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Country (U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa) Industry Trends and Forecast to 2029.
Market Analysis and Insights Global Transthyretin Amyloid Cardiomyopathy Treatment Market
The transthyretin amyloid cardiomyopathy treatment market is expected to witness market growth at a rate of 25.1% in the forecast period of 2022 to 2029, and is estimated to reach the value of USD 29283.20 million by 2029. Data Bridge Market Research report on transthyretin amyloid cardiomyopathy treatment market provides analysis and insights regarding the various factors expected to be prevalent throughout the forecast period while providing their impacts on the market’s growth. The rise in healthcare sector globally is escalating the growth of transthyretin amyloid cardiomyopathy treatment market.
Transthyretin amyloid cardiomyopathy (ATTR-CM) refers to a form of transthyretin amyloidosis (ATTR) that tends to affect the heart. This condition leads to restrictive cardiomyopathy and progressive heart failure. The disorder is known to be a rare, underdiagnosed, and life-threatening disease and causes damage to the heart’s muscles.
The surge in the number of people suffering from transthyretin amyloid cardiomyopathy across the globe acts as one of the major factors driving the growth of transthyretin amyloid cardiomyopathy treatment market. The increase in demand for specific drugs for treating symptoms of the rare disorder and improvement in diagnostic procedures for better diagnosis accelerate the market growth. The increase in in number of clinical trials for enhancement of drugs and therapies, and high focus on research and development of transthyretin amyloid cardiomyopathy (ATTR-CM) treatment further influence the market. Additionally, rise in healthcare expenditure, research and development activities, growth in awareness and improvement of healthcare services positively affect the transthyretin amyloid cardiomyopathy treatment market. Furthermore, development of a novel drug products extend profitable opportunities to the market players in the forecast period of 2022 to 2029.
On the other hand, high cost associated with the treatment and lack of diagnosis are expected to obstruct the market growth. Lack of skilled professionals is projected to challenge the transthyretin amyloid cardiomyopathy treatment market in the forecast period of 2022-2029.
This transthyretin amyloid cardiomyopathy treatment market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info transthyretin amyloid cardiomyopathy treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Transthyretin Amyloid Cardiomyopathy Treatment Market Scope and Market Size
The transthyretin amyloid cardiomyopathy treatment market is segmented on the basis of drug, indication, distribution channel and end-users. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of product type, the transthyretin amyloid cardiomyopathy treatment market is segmented into inostersen, nonsteroidal anti-inflammatory drugs (NSAID), partisiran, tafamidis and others.
- On the basis of Indication, the transthyretin amyloid cardiomyopathy treatment market is segmented into wild type ATTR amyloidosis and hereditary ATTR amyloidosis.
- On the basis of distribution channel, the transthyretin amyloid cardiomyopathy treatment market is segmented into hospital pharmacy, retail pharmacy and online pharmacy.
- On the basis of end-users, the transthyretin amyloid cardiomyopathy treatment market is segmented into hospitals, homecare, specialty clinics and others.
Transthyretin Amyloid Cardiomyopathy Treatment Market Country Level Analysis
The transthyretin amyloid cardiomyopathy treatment market is analyzed and market size information is provided by country, drug, indication, distribution channel and end-users as referenced above.
The countries covered in the global transthyretin amyloid cardiomyopathy treatment market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).
North America dominates the transthyretin amyloid cardiomyopathy treatment market due to the increase in the number of diagnosis procedures and presence of leading manufacturers within the region. Asia-Pacific is expected to witness high growth during the forecast period of 2022 to 2029 because of the expansion of the pharmaceutical industry in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
The transthyretin amyloid cardiomyopathy treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Transthyretin Amyloid Cardiomyopathy Treatment Market Share Analysis
The transthyretin amyloid cardiomyopathy treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related transthyretin amyloid cardiomyopathy treatment market.
Some of the major players operating in the transthyretin amyloid cardiomyopathy treatment market are Merck & Co., Inc., Pfizer Inc., AstraZeneca, Prothena Corporation plc., Ionis Pharmaceuticals, BELLUS Health Inc., Alnylam Pharmaceuticals, Inc.., Prothena, GlaxoSmithKline plc., Eidos Therapeutics, and SOM BIOTECH, among others.
SKU-